Connect Biopharma Reports Topline Results from Phase 2 Trial of CBP-201 for Moderate-to-Severe Atopic Dermatitis

Connect Biopharma Reports Topline Results from Phase 2 Trial of CBP-201 for Moderate-to-Severe Atopic Dermatitis

Connect Biopharma reported results from the global Phase 2 clinical trial of subcutaneously administered CBP-201 in adult patients with moderate-to-severe atopic dermatitis (AD). Although no specific data were reported, the company stated that the trial met its primary endpoint - with all three CBP-201 arms achieving significant improvements over placebo, as well as secondary endpoints. Significant improvements were reported for additional key secondary endpoints. The company plans to initiate a phase 3 trial program in mid-2022.

The randomized, double-blind, placebo-controlled study enrolled 226 patients (ages 18–75 years) throughout the United States, China, Australia, and New Zealand. Patients were randomized to one of three CBP-201 treatment groups or the placebo group. The CBP-201 treatment groups all received a 600 mg loading dose on Day 1 and then received 300 mg every two weeks (Q2W), 150 mg Q2W or 300 mg Q4W. The treatment period was 16 weeks, and all patients were followed for an additional period of 8 weeks.

The primary efficacy endpoint was the percentage reduction in the Eczema Area and Severity Index (EASI) score from baseline to Week 16 for each CBP-201 group ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee